ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1065

Artesunate Can Synergize with Methotrexate on Inhibiting Migration and Invasion of Fibroblast-like Synoviocytes from Patients with Rheumatoid Arthritis

Jian-Da Ma1, Jun Jing1, Jun-Wei Wang1, Tao Yan2, Yun-Shan Mou2, Ying-Qian Mo1 and Lie Dai1, 1Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China, 2Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Fibroblasts, methotrexate (MTX) and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Etiology and Pathogenesis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Fibroblast-like synoviocytes (FLS) play important roles on joint destruction in rheumatoid arthritis (RA). Recent reports showed that antimalaria drug artesunate presents anti-cancer potential by suppressing cancer cells invasion and metastasis. We have found that artesunate could inhibit migration and invasion of RA-FLS as well as MMP-2/9 expression. Methotrexate (MTX) is the anchor drug for RA treatment. Here we aimed to investigate the synergistic effect of artesunate with MTX on inhibiting aggressive ability of RA-FLS.

Methods: Synovial tissues were obtained by closed needle biopsy from 6 active RA patients and FLS were isolated. Primary RA-FLS were cultured in vitro and pretreated with 60¦ÌM artesunate, 10nM MTX, or combination of 60¦ÌM artesunate and 2.5nM~10nM MTX respectively for indicated times. Their effects on cell viability and proliferation were measured by CCK-8 assay, while effects on migration and invasion capacity of RA-FLS were detected by wound healing and transwell assays. Differential expression of MMP-2/9 and tissue inhibitors of metalloproteinases (TIMP) -1/2 were detected by quantitative real-time PCR, western blot and ELISA.

Results: (1) Compared with untreated group, 60¦ÌM artesunate, 10nM MTX or combination of 60¦ÌM artesunate and 2.5nM~10nM MTX showed no significant effect on cell viability and proliferation of RA-FLS for 72 hours (Fig 1A). (2) Both 60¦ÌM artesunate and10nM MTX alone significantly inhibited migration and invasion of RA-FLS. The combination of 60¦ÌM artesunate and 7.5nM MTX had stronger inhibitory effect on migration and invasion than 60¦ÌM artesunate or 10nM MTX alone (Fig 1B). (3) Both 60¦ÌM artesunate and10nM MTX alone significantly inhibited MMP-2/9 expression but promoted the expression of TIMP-2. The combination of 60¦ÌM artesunate and 7.5nM MTX had stronger effect on regulating MMP-9 and TIMP-2 than 60¦ÌM artesunate or 10nM MTX alone (Fig 1C).

Conclusion: Artesunate can synergize with MTX on inhibiting migration and invasion of primary RA-FLS by inhibiting MMP-9 and promoting TIMP-2 expression, which implies the potential of combination therapy of artesunate and MTX for RA.

Fundings: This work was supported by National Natural Science Foundation of China (no. 81471597, 81671612), Guangdong Natural Science Foundation (no. 2017A030313576, 2017A030310236) and Scientific Program of Traditional Chinese Medicine Bureau of Guangdong Province (no. 20161058, 20181058).



Disclosure: J. D. Ma, None; J. Jing, None; J. W. Wang, None; T. Yan, None; Y. S. Mou, None; Y. Q. Mo, None; L. Dai, None.

To cite this abstract in AMA style:

Ma JD, Jing J, Wang JW, Yan T, Mou YS, Mo YQ, Dai L. Artesunate Can Synergize with Methotrexate on Inhibiting Migration and Invasion of Fibroblast-like Synoviocytes from Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/artesunate-can-synergize-with-methotrexate-on-inhibiting-migration-and-invasion-of-fibroblast-like-synoviocytes-from-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/artesunate-can-synergize-with-methotrexate-on-inhibiting-migration-and-invasion-of-fibroblast-like-synoviocytes-from-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology